March 2018 in “Trends in Immunotherapy” In this study, triamcinolone acetonide injections led to partial hair regrowth in 60% of alopecia totalis patients, suggesting potential benefits when followed by immunotherapy.
January 2023 in “Cutaneous and Ocular Toxicology” This study found that ATP may help reduce ribociclib-induced skin damage in rats by mitigating biochemical changes associated with oxidative stress.
1 citations
,
September 2007 in “Neuromuscular disorders” This study suggests that long-term treatment with valproate, acetylcarnitine, folic acid, and vitamin B12 may benefit children with SMA types II and III by improving muscle strength and function without significant adverse effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This document promotes an Erthwellness discount code that offers a 25% reduction on all their natural health products, without presenting any new research findings.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.
January 2023 in “Pharmaceutics” In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.
April 2026 in “Dermatology Practical & Conceptual” This study suggests that autologous micrograft technology may be more effective than finasteride in promoting hair growth in patients with androgenetic alopecia.
April 2020 in “Trends in Immunotherapy” In this study, 60% of patients with alopecia totalis showed partial hair regrowth after being treated with triamcinolone acetonide injections, with one patient achieving complete regrowth and responding well to further immunotherapy.
January 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.
65 citations
,
February 2015 in “Neuro-Oncology” In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.
15 citations
,
June 2016 in “Computers in Biology and Medicine” This study's simulation found that Ascorbyl Tetraisopalmitate penetrates more efficiently through the skin's stratum corneum than via the infundibulum, following different pathways and dynamics in each membrane.
September 2026 in “Apollo Medicine” In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
June 2026 in “Journal of Investigative Dermatology” Retinoic acids temporarily change skin stem cells to a slower cycle and more differentiated state.
April 2016 in “Journal of Investigative Dermatology” This study found that administering botulinum toxin A via Flex-PADs to mouse footpads inhibited sweating similarly to traditional injections, suggesting a promising patient-friendly delivery method for hyperhidrosis treatment.
11 citations
,
January 2018 in “Acta dermato-venereologica” In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.
2 citations
,
January 2018 in “Journal of clinical & experimental dermatology research” This study suggests that AT-ASCs significantly improve terminal and intermediate hair counts and hair caliber in androgenetic alopecia more than PRP, though with more side effects like headache and erythema.
3 citations
,
April 2021 in “Oncology Times” This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.
24 citations
,
December 2010 in “Dermatologic surgery” In this study, BTXA injections did not effectively treat recalcitrant alopecia areata or improve hair regrowth in most patients, suggesting its limitations as an alternative therapy.
1 citations
,
September 2023 In this study, autologous micrografting technology using auricular cartilage was reported to be safe and effective for improving knee function and reducing symptoms in patients with early-stage knee osteoarthritis over six months, but larger studies are needed to confirm these results.
April 2017 in “Journal of Investigative Dermatology” This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.
June 2026 in “British Journal of Dermatology” This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.
31 citations
,
May 2017 in “JAAD Case Reports” This article reviews the use of deoxycholic acid as a nonsurgical treatment for unwanted fat in the cosmetic field but reports no new clinical results.
5 citations
,
March 2023 in “PubMed” This review discusses the potential of advanced therapy medicinal products for treating vitiligo, highlighting promising results but noting affordability remains a challenge; no new clinical results were reported.
4 citations
,
January 2023 in “Pharmacology” This study found that euthyroid women with Hashimoto’s thyroiditis experienced less benefit from atorvastatin treatment in terms of cardiometabolic marker improvements compared to women with hypercholesterolemia but without thyroid issues, indicating a differential response in these populations.
64 citations
,
August 2019 in “Circulation” This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.
January 2024 in “Research Portal Denmark” This thesis reveals that tenuazonic acid inhibits plant plasma membrane H+-ATPase, suggesting its potential as a herbicide due to its impact on root elongation and cell viability in Arabidopsis thaliana.